Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Application of systems biology to identify pharmacological mechanisms of thrombotic microangiopathy evoked by combined activated prothrombin complex concentrate and emicizumab

Autor: Raquel Valls, Jonathan Wagg, Ido Paz-Priel, Gabriel Man, Laura Artigas, Georges Jaccard, Mireia Coma, Christophe Schmitt

Publikováno v: Scientific Reports, Vol 13, Iss 1, Pp 1-11 (2023)

Abstract Emicizumab is a bispecific monoclonal antibody that substitutes for the function of missing or deficient factor VIII (FVIII) in people with hemophilia A (PwHA). Long-term safety and efficacy of emicizumab have been demonstrated in several cl

Externí odkaz: https://doaj.org/article/68bbdf85ad8f4b31a93b4b1a45d37773

Reduced Volume and Faster Infusion Rate of Activated Prothrombin Complex Concentrate: A Phase 3b/4 Trial in Adults with Hemophilia A with Inhibitors.

Autor: Zülfikar B; Hereditary Bleeding Disorders Unit in Oncology Institute, Istanbul University, Istanbul, Turkey., Mahlangu J; Department of Molecular Medicine and Haematology, Faculty of Health Sciences, University of the Witwatersrand and NHLS, Johannesburg, South Africa., Nekkal SM; CHU Isaad Hassani, Beni Messous, Algiers, Algeria., Ross C; St John's Medical College Hospital, Bangalore, India., Uaprasert N; Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand.; Center of Excellence in Translational Hematology, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand., Windyga J; Department of Hemostasis Disorders and Internal Medicine, Laboratory of Hemostasis and Metabolic Diseases, Institute of Hematology and Transfusion Medicine, Warsaw, Poland., Ettingshausen CE; Haemophilia Centre Rhein Main, Frankfurt-Mörfelden, Germany., Ploder B; Baxalta Innovations GmbH, a Takeda company, Vienna, Austria., Lelli A; PDT R&D Global Medical Affairs, Takeda Pharmaceuticals International AG, Zurich, Switzerland., Gazda HT; Takeda Development Center Americas, Inc., Cambridge, Massachusetts, United States.

Publikováno v: TH open : companion journal to thrombosis and haemostasis [TH Open] 2024 Jul 08; Vol. 8 (3), pp. e273-e282. Date of Electronic Publication: 2024 Jul 08 (Print Publication: 2024).

Activated prothrombin complex concentrate to treat bleeding events in acquired hemophilia A: BAHAS study.

Autor: Mingot‐Castellano, María E.^1,2 (AUTHOR) mariae.mingot.sspa@juntadeandalucia.es, García‐Candel, Faustino³ (AUTHOR), Benítez‐Hidalgo, Olga⁴ (AUTHOR), Marco, Ana⁵ (AUTHOR), Méndez Navarro, Gala A.⁶ (AUTHOR), Pérez‐Montes, Rocío⁶ (AUTHOR), García Donas, Gloria⁷ (AUTHOR), Canaro, Mariana⁸ (AUTHOR), Paloma, María J.⁹ (AUTHOR), Asenjo, Beatríz¹⁰ (AUTHOR), Calle‐Gordo, Victoria M.¹¹ (AUTHOR), González, Noelia P.¹¹ (AUTHOR), Rodríguez González, Ramón¹² (AUTHOR), Caparrón‐Miranda, Isabel S.¹³ (AUTHOR), Quintana París, Laura¹⁴ (AUTHOR), Herrero, Sonia¹⁵ (AUTHOR), Nuñez, Ramiro¹ (AUTHOR)

Publikováno v: European Journal of Haematology. Dec2022, Vol. 109 Issue 6, p686-695. 10p.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.